To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Locums: Qualifications
Tuesday 10th November 2015

Asked by: Paul Flynn (Labour - Newport West)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate he has made of the cost of locums to the NHS arising from the General Medical Council's revalidation programme.

Answered by Ben Gummer

Medical revalidation is underpinned by structured appraisal processes that support a doctor's professional development. Doctors will prepare for their appraisal during planned periods away from clinical practice, thus removing the need for additional locum cover in the National Health Service.

Written Question
Naloxone
Tuesday 10th November 2015

Asked by: Paul Flynn (Labour - Newport West)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate he has made of potential savings to the NHS arising from an expansion of the availability of Take-Home Naloxone.

Answered by Jane Ellison

No estimate has been made of the potential savings to the National Health Service arising from expanding the availability of take-home naloxone.


The Advisory Council on the Misuse of Drugs’ ‘Consideration of naloxone’ (2012) reported that there is a lack of published research on the cost-effectiveness of naloxone provision and said that naloxone provision in local areas would be a local decision including an assessment of its cost-effectiveness.


To help local areas introduce effective and efficient take-home services, Public Health England published advice on promoting wider availability of naloxone to reduce overdose deaths in February 2015.

Speech in Commons Chamber - Fri 06 Nov 2015
Off-patent Drugs Bill

"rose—..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: Off-patent Drugs Bill
Speech in Commons Chamber - Fri 06 Nov 2015
Off-patent Drugs Bill

"I have long known the right hon. Gentleman and greatly respect him, but today the House has spoken on this with one voice, from both sides, with expert opinion and personal opinion. Only one voice has been silent in this debate, and that is the voice of the industry, the …..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: Off-patent Drugs Bill
Speech in Commons Chamber - Fri 06 Nov 2015
NHS (Charitable Trusts Etc.) Bill

"The hon. Lady has twice mentioned the need for charities to be free from regulation and Government involvement. Will she study the recent history of Kids Company, which has been accused of many abuses, and certainly a great waste of public money, as a result of lax regulation and the …..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: NHS (Charitable Trusts Etc.) Bill
Speech in Commons Chamber - Fri 06 Nov 2015
NHS (Charitable Trusts Etc.) Bill

"Will the hon. Gentleman give way?..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: NHS (Charitable Trusts Etc.) Bill
Speech in Commons Chamber - Fri 06 Nov 2015
NHS (Charitable Trusts Etc.) Bill

"There are 5,000 leading charities in Britain, and there is great concern about the activities of some of them. The majority do a great deal of good, but we know of the abuses carried out by “chuggers”—which constitute robbery as far as donors are concerned—and the use of call centres …..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: NHS (Charitable Trusts Etc.) Bill
Speech in Commons Chamber - Fri 06 Nov 2015
NHS (Charitable Trusts Etc.) Bill

"There is a current example of grotesque jobbery in the appointment by the Prime Minister of the Conservative Members of the Council of Europe, and three splendid Members, including the hon. Member for Christchurch (Mr Chope), have been—..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: NHS (Charitable Trusts Etc.) Bill
Speech in Commons Chamber - Fri 06 Nov 2015
Off-patent Drugs Bill

"The right hon. Gentleman prays in aid the MHRA, which is entirely funded by the pharmaceutical industry. Why does he not confess that he has taken this cruel and unfair stand of following what the industry has told him to maximise its profits and put patients last?..."
Paul Flynn - View Speech

View all Paul Flynn (Lab - Newport West) contributions to the debate on: Off-patent Drugs Bill
Written Question
Opiates
Wednesday 4th November 2015

Asked by: Paul Flynn (Labour - Newport West)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the recent trends in opioid prescribing.

Answered by Alistair Burt

Information is not held centrally for numbers of prescription items written. The table provides both the numbers of prescription items dispensed for opioid medicines in England, as defined by the British National Formulary (BNF) Section 4.7.2 opioid analgesics, and an analysis of prescribing trends, for the last 15 calendar years, using England population figures.


Number of prescription items and prescription items per 1,000 of population in England, for opioids, as defined by BNF 4.7.2, based on prescriptions written in the United Kingdom and dispensed in the community, in England.



Year

Prescription items (thousands)1

Items per 1,000 population 2

% change in prescription items 2

% change in items per 1,000 population 2

2000

6,818.9

138.5

-

-

2001

7,462.1

150.9

9.4

9.0

2002

8,077.4

162.6

8.2

7.7

2003

8,731.1

174.9

8.1

7.6

2004

9,498.3

189.2

8.8

8.2

2005

10,709.9

211.6

12.8

11.8

2006

11,960.2

234.7

11.7

10.9

2007

13,408.8

261.0

12.1

11.2

2008

14,843.0

286.5

10.7

9.8

2009

16,270.5

311.7

9.6

8.8

2010

17,689.0

336.0

8.7

7.8

2011

19,124.4

360.1

8.1

7.2

2012

20,552.3

384.2

7.5

6.7

2013

21,710.3

403.0

5.6

4.9

2014

22,748.8

418.8

4.8

3.9

Source:

1 Prescription Cost Analysis (PCA) system data provided by the Health and Social Care Information Centre

2 Analysis based on Office of National Statistics population statistics for England